Market Research Report 2017 The Oncolytic Virus Landscape Industry Trends
2017 The Oncolytic Virus Landscape Industry Trends & Opportunities Market Research Hub has recently announced the addition of a new report to it broad database titled as “ The Oncolytic Virus Landscape 2017 : an analysis of pipeline , stakeholders , deals , industry trends & opportunities ”. The field of oncolytic viruses was quite dormant in the first decade of the 2000s , characterized by slow clinical progress due to hypercautiousness and low , albeit steady , investments .
The Oncolytic Virus Landscape 2017 : an analysis of pipeline , stakeholders , deals , industry trends & opportunities
The takeover of BioVex by Amgen in late 2011 , worth up to US $ 1 bln , has woken up the field and became a game changer together with the 2015 approval of the first oncolytic virus Imlygic developed by BioVex in regulated markets . In addition , it was increasingly recognized that oncolytic viruses not only were able to directly lyse cancer cells , but they also „ freed “ tumor specific neoantigens , indirectly acting as a cancer vaccine .
However , the efficacy of oncolytic viruses still was modest , but can be improved when combined with immune checkpoint inhibitors . This lead to an increased partnering interest of the major immuno-oncology ( I-O ) players , but also of investors who view oncolytic viruses as a must be for I-O combination regimens . As a consequence , total venture equity and